Lansing、MIにおける肺がんの臨床試験
Lansingとその周辺地域（約30マイル以内）の拠点で、肺がんに関する11件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
被験者募集中第3相
- University of Michigan Health - Sparrow Lansing, Lansing
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- University of Michigan Health - Sparrow Lansing, Lansing
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
被験者募集中第3相
- University of Michigan Health - Sparrow Lansing, Lansing
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
被験者募集中第3相
- University of Michigan Health - Sparrow Lansing, Lansing
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
被験者募集中第3相
- University of Michigan Health - Sparrow Lansing, Lansing
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
被験者募集中第3相
- Karmanos Cancer Institute at McLaren Greater Lansing, Lansing
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
被験者募集中第3相
- Karmanos Cancer Institute at McLaren Greater Lansing, Lansing
- University of Michigan Health - Sparrow Lansing, Lansing
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
被験者募集中第2相
- University of Michigan Health - Sparrow Lansing, Lansing
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2相
- University of Michigan Health - Sparrow Lansing, Lansing
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2/3相
- University of Michigan Health - Sparrow Lansing, Lansing
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Lansing
他の都市における肺がんの試験
- Houston, TX78件の研究
- Boston, MA62件の研究
- New York City, NY60件の研究
- Los Angeles, CA45件の研究
- Washington, DC41件の研究
- Arlington, VA41件の研究
- Chicago, IL41件の研究
- Nashville, TN40件の研究
- Baltimore, MD40件の研究
- St. Louis, MO39件の研究
- Columbus, OH37件の研究
- Philadelphia, PA36件の研究
Lansingにおける他の研究
- 前立腺がん10件の研究
- 乳がん10件の研究
- 非小細胞肺癌9件の研究
- がん（全種類）6件の研究
- 喉頭がん5件の研究
- 膀胱癌5件の研究
- 過眠症5件の研究
- 大腸癌4件の研究
- 腎臓がん（腎細胞がん）4件の研究
- 結腸癌4件の研究
- 尿路上皮（移行上皮）癌4件の研究
- 頭頸部扁平上皮癌4件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。